Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics

Yoshio Ozaki, Shosaku Nomura First Department of Internal Medicine, Kansai Medical University, Hirakata, JapanCorrespondence: Shosaku NomuraFirst Department of Internal Medicine, Kansai Medical University, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1010, JapanTel +81 72 804 2754Fax +81 72 804 2041Email s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ozaki Y, Nomura S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	connective tissue disease-related intractable disease biological therapeutics clinical practice inflammatory cytokine Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/ef381309e5a643cabfada7eb4d6a9ba6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ef381309e5a643cabfada7eb4d6a9ba6
record_format	dspace
spelling	oai:doaj.org-article:ef381309e5a643cabfada7eb4d6a9ba62021-12-02T17:29:56ZTreatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics1179-156Xhttps://doaj.org/article/ef381309e5a643cabfada7eb4d6a9ba62021-09-01T00:00:00Zhttps://www.dovepress.com/treatment-of-connective-tissue-disease-related-intractable-disease-wit-peer-reviewed-fulltext-article-OARRRhttps://doaj.org/toc/1179-156XYoshio Ozaki, Shosaku Nomura First Department of Internal Medicine, Kansai Medical University, Hirakata, JapanCorrespondence: Shosaku NomuraFirst Department of Internal Medicine, Kansai Medical University, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1010, JapanTel +81 72 804 2754Fax +81 72 804 2041Email shosaku-n@mbp.ocn.ne.jpAbstract: The treatment of connective tissue disease (CTD) and CTD-related intractable diseases (CTD-IDs) currently depends on the use of steroid therapy. Approximately 20 years have passed since the approval of infliximab for rheumatoid arthritis in 2003. Since then, several biological therapeutics have been marketed and adapted for many CTDs and CTD-IDs other than rheumatoid arthritis. Although conventional treatment for patients with these diseases is rarely used because of their poor prognosis, these cases may benefit from biological therapeutics. However, choosing biological therapeutics is difficult because they have different target molecules compared with conventional therapeutics. In this review, we address the current situation of biological therapeutics for CTD-IDs including Behcet’s disease, psoriatic arthritis, ankylosing spondylitis, anti-neutrophil cytoplasmic antibody-related arthritis, and adult Still’s disease, as well as the choice of biological therapeutics in clinical practice.Keywords: connective tissue disease-related intractable disease, biological therapeutics, clinical practice, inflammatory cytokineOzaki YNomura SDove Medical Pressarticleconnective tissue disease-related intractable diseasebiological therapeuticsclinical practiceinflammatory cytokineDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 13, Pp 293-303 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	connective tissue disease-related intractable disease biological therapeutics clinical practice inflammatory cytokine Diseases of the musculoskeletal system RC925-935
spellingShingle	connective tissue disease-related intractable disease biological therapeutics clinical practice inflammatory cytokine Diseases of the musculoskeletal system RC925-935 Ozaki Y Nomura S Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics
description	Yoshio Ozaki, Shosaku Nomura First Department of Internal Medicine, Kansai Medical University, Hirakata, JapanCorrespondence: Shosaku NomuraFirst Department of Internal Medicine, Kansai Medical University, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1010, JapanTel +81 72 804 2754Fax +81 72 804 2041Email shosaku-n@mbp.ocn.ne.jpAbstract: The treatment of connective tissue disease (CTD) and CTD-related intractable diseases (CTD-IDs) currently depends on the use of steroid therapy. Approximately 20 years have passed since the approval of infliximab for rheumatoid arthritis in 2003. Since then, several biological therapeutics have been marketed and adapted for many CTDs and CTD-IDs other than rheumatoid arthritis. Although conventional treatment for patients with these diseases is rarely used because of their poor prognosis, these cases may benefit from biological therapeutics. However, choosing biological therapeutics is difficult because they have different target molecules compared with conventional therapeutics. In this review, we address the current situation of biological therapeutics for CTD-IDs including Behcet’s disease, psoriatic arthritis, ankylosing spondylitis, anti-neutrophil cytoplasmic antibody-related arthritis, and adult Still’s disease, as well as the choice of biological therapeutics in clinical practice.Keywords: connective tissue disease-related intractable disease, biological therapeutics, clinical practice, inflammatory cytokine
format	article
author	Ozaki Y Nomura S
author_facet	Ozaki Y Nomura S
author_sort	Ozaki Y
title	Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics
title_short	Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics
title_full	Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics
title_fullStr	Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics
title_full_unstemmed	Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics
title_sort	treatment of connective tissue disease-related intractable disease with biological therapeutics
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/ef381309e5a643cabfada7eb4d6a9ba6
work_keys_str_mv	AT ozakiy treatmentofconnectivetissuediseaserelatedintractablediseasewithbiologicaltherapeutics AT nomuras treatmentofconnectivetissuediseaserelatedintractablediseasewithbiologicaltherapeutics
_version_	1718380763886387200

Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics

Ejemplares similares